ad image

ALK Inhibitor Naïve

1 / 1
Takeda
Phase III Trial

Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint Demonstrating Superiority in Progression-Free Survival Versus Crizotinib

Takeda

PR-M07-18-NI-094Jul 27, 2018
1 / 1